The Next Generation Pregnancy Initiative supports research in the following priority areas:
|
|
|
|
Bleeding Disorders Canada, formerly the Canadian Hemophilia Society (CHS), is proud to announce its call for applications for its research programs for the 2026–2027 grant period.
The Canadian Hemophilia Society became Bleeding Disorders Canada in July 2026. During this transition period, research grant documents may include references to both Bleeding Disorders Canada and the Canadian Hemophilia Society (CHS) as we update our materials to reflect our new name.
The deadline to submit applications for all the programs is NOVEMBER 27, 2026. Please see below details of each research grant and links to apply. Feel free to reach out to Natalie Philbert, National Programs Director, if you have any questions or require assistance at nphilbert@hemophilia.ca.
DREAM OF A CURE
The CHS provides scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, and platelet function disorders.
Individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years.
Grants will also be available for Canadian medical or science students for up to 4 months, for a maximum stipend of $6,000 each.
Examples of previous research awarded include: Human Endometrial Endothelial Cells (HEECs): A novel cellular method for understanding the pathophysiology of heavy menstrual bleeding in von Willebrand Disease by Dr. Mackenzie Bowman & Dr. Paula James
Online applications for the 2026-27 granting period, previous and current research, as well as the general criteria and conditions can be accessed at: www.hemophilia.ca/chs-dream-of-a-cure-research-program.
______________________________
PFIZER CARE UNTIL CURE RESEARCH PROGRAM
In partnership with Pfizer, the CHS provides research grants to Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including hemophilia, people with von Willebrand disease or other inherited bleeding disorders, people with related conditions such as HIV or hepatitis C infection, and carriers of an inherited bleeding disorder.
Individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years.
Examples of previous research awarded include: A Canadian Roadmap and Action Plan for Hemophilia Gene Therapies: A Mixed-Method Study by Dr. Roy Khalifé
Online application forms for the 2026-27 granting period, previous and current research, general criteria and specific areas of interest can be accessed at: www.hemophilia.ca/the-chspfizer-care-until-cure-research-program
Please feel free to distribute this information to others who may be interested in applying. The research must be conducted in Canada by researchers affiliated with Canadian universities and not-for-profit-related organizations.
|
|---|
The Project Grant program is expected to:
The PCC Fellowship Program supports qualified scientists interested in the field of anti-doping, committed to meaningful research, and demonstrating potential for long-term contribution to the field of anti-doping science. Fellows selected by the PCC participate in a two-year program. Fellows gain practical knowledge from a U.S.-based, WADA-accredited laboratory and conduct research supporting the anti-doping field.
PCC Research Grants support projects advancing knowledge in the anti-doping sphere. Pre-Applications are reviewed two times per year: February 1st and August 1st. Applicants are encouraged to review the research priorities of the PCC before applying. Applicants that are invited to complete a full application, are encouraged to review the instructions below. Full Applications are due on March 1st and September 1st.
Successful applicants will be enrolled in the program for up to two years and will benefit from comprehensive capacity-building opportunities and support, including:
